RxDoctor Payments Data

Stephen Saunders, MD

Psychiatry · Towson, MDNPI 1750400412

Payments from drug & device makers

$1,395in general payments, 2019–2025

Across 40 payments — averaging $34.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$528
  • AbbVie$264
  • Avanir Pharmaceuticals, Inc.$144
  • Sunovion Pharmaceuticals Inc.$141
  • Lundbeck LLC$73
  • Adlon Therapeutics L.p.$61
  • plus $184 from 5 others

What the payments were for

  • Food & beverage$1,393100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,395 in reported general payments places this provider in the 80th percentile of 851 psychiatry providers in Maryland.

See all psychiatry providers in Maryland

Medicare billing

Part B allowed, 2024
$81,610
Medicare patients
22
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole19$25,807
VyvanseLisdexamfetamine Dimesylate31$11,104
Ziprasidone Hcl38$1,834
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$1,456
Venlafaxine Hcl ErVenlafaxine Hcl22$1,308
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine41$1,269
Alprazolam124$1,180
Zolpidem Tartrate49$1,170
Cyclobenzaprine Hcl20$1,034
Methylphenidate Hcl12$568
Bupropion Hcl SrBupropion Hcl29$534
Mirtazapine19$516
Trazodone Hcl45$396
Gabapentin24$286
Fluoxetine Hcl37$285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$528$25,80719 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$41$11,10431 claims
Almatica Pharma LLCSertraline Hcl$26$5113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 851 psychiatry providers in Maryland.

Other psychiatry in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →